Peripheral Angioplasty Market (2025 - 2035)

Peripheral Angioplasty Market Size and Share Forecast Outlook (2025 to 2035)

The peripheral angioplasty Market is valued at USD 3.66 billion in 2025. As per FMI's analysis, the industry will grow at a CAGR of 7.7% and reach USD 7.7 billion by 2035. The peripheral angioplasty industry is expected to witness robust growth over the next decade, driven by the rising incidence of peripheral artery disease (PAD), increasing geriatric population, and growing demand for minimally invasive procedures.

Technological advancements in angioplasty devicessuch as drug-coated balloons and next-generation stentsare expected to improve patient outcomes and reduce recurrence, thus supporting long-term industry expansion.

Favorable reimbursement policies and expanding healthcare infrastructure, especially in emerging economies, will further boost the adoption of peripheral angioplasty. North America will maintain its dominance due to early technology adoption and high prevalence of PAD, while Asia Pacific is projected to register the fastest growth owing to improving diagnostics and rising health awareness.

Metric	Value
Industry Value (2025E)	USD 3.66 billion
Industry Value (2035F)	USD 7.7 billion
CAGR (2025 to 2035)	7.7%

Peripheral Angioplasty Industry Analysis and Trends

The peripheral angioplasty industry is on a sustained growth trajectory, driven by rising global prevalence of peripheral artery disease and a strong shift toward minimally invasive treatment options. Technological innovation in balloon catheters and stents is enhancing procedure efficacy and long-term patient outcomes. Stakeholders who invest in R&D, outpatient service expansion, and emerging industries stand to gain the most, while those slow to adopt innovation risk losing industry share.

Top 3 Strategic Imperatives for Stakeholders

Accelerate Innovation in Device Technology

Invest in the development of next-generation drug-coated balloons and bioresorbable scaffolds to increase procedural success and reduce restenosis.

Align with Shifting Care Models

Focus on outpatient care expansion and value-based care models that emphasize faster recovery and cost efficiency.

Expand Through Partnerships and Regional Penetration

Pursue strategic partnerships with regional hospitals and clinics in Asia-Pacific and Latin America; consider M&A for tech integration and faster industry entry.

Risks Stakeholders should Monitor

Risk	Probability - Impact
Supply chain disruptions for catheter components	Medium - High
Regulatory delays in emerging industries	High - Medium
Rising competition from alternative PAD therapies	Medium - Medium

1-Year Executive Watchlist

Priority	Immediate Action
Develop regional go-to- industry plan	Run feasibility on expanding in APAC and Latin America
Advance catheter innovation	Initiate OEM feedback loop on drug-coated balloon designs
Strengthen channel incentives	Launch aftermarket channel partner incentive pilot

For the Boardroom

The next decade in peripheral angioplasty will be defined by innovation, outpatient care models, and global industry penetration. Companies must prioritize device enhancement and invest in fast-growing regions to capture upcoming demand shifts.

Leadership should recalibrate their strategic roadmap to integrate agile R&D cycles, forge ecosystem partnerships, and scale value-based service delivery. Acting now will secure long-term positioning as a front-runner in the next phase of PAD treatment evolution.

FMI Survey Results: Peripheral Angioplasty Market Dynamics based on Stakeholder Perspectives

(Surveyed Q4 2024, n=450 stakeholder participants evenly distributed across medtech manufacturers, hospital procurement heads, interventional cardiologists, and health insurance firms in the USA, Western Europe, India, China, and Japan)

Key Priorities of Stakeholders

• Procedure Success Rate: 85% of stakeholders globally rated high long-term patency and low restenosis rates as their top requirement.
• Minimally Invasive Options: 78% highlighted strong preference for non-surgical interventions that reduce hospital stay.

Regional Variance

• USA: 72% ranked post-angioplasty care pathways and outpatient follow-up as critical.
• Western Europe: 81% prioritized sustainability in device materials and packaging, reflecting the region's green mandates.
• India/China: 67% emphasized affordability and broader accessibility in Tier 2/3 hospitals.
• Japan: 61% stressed on reduced procedural time to manage high patient turnover in aging populations.

Adoption of Advanced Technologies

High Variance

• USA: 64% of hospitals use drug-coated balloons (DCBs), with 42% integrating AI-assisted imaging.
• Western Europe: 58% of hospitals reported growing use of next-gen bioresorbable scaffolds.
• India: 31% have piloted AI tools for PAD diagnosis but struggle with integration costs.
• Japan/China: Only 28% adopted real-time imaging guidance due to device cost and regulatory clearance delays.

ROI Perspectives

• 69% of USA and European stakeholders reported measurable ROI from adopting DCBs, whereas 54% of Indian hospitals indicated ROI challenges due to high device import costs.

Material & Device Preferences

Consensus

• Stainless steel stents preferred by 62% overall for durability and compatibility.

Regional Variance

• Western Europe: 48% preferred polymer-coated systems to meet biocompatibility and EU safety norms.
• China/India: 57% opted for cost-efficient bare-metal balloon systems for public hospital use.
• Japan: 44% favored hybrid catheter designs (low-profile, dual-layered) for narrow vessel access.

Price Sensitivity

Shared Challenges

• 82% cited rising cost of imported components and inflation-driven pricing as key issues.

Regional Differences

• USA/Europe: 66% were open to a 10-15% premium for DCBs or imaging-guided delivery systems.
• India/China: 73% preferred bundled packages from domestic suppliers; 61% demanded under-USD 2,500 per device.
• Japan: 38% wanted leasing options for imaging consoles to avoid capex burden.

Pain Points in the Value Chain

Manufacturers

• USA: 58% reported challenges in FDA regulatory backlog for next-gen angioplasty tools.
• Europe: 51% cited MDR delays affecting time-to-market.
• India: 65% flagged difficulty accessing catheter-grade polymers locally.

Hospitals/Procurement Heads

• USA: 47% cited extended training cycles for adopting AI-integrated systems.
• Europe: 42% struggled with vendor fragmentation.
• China/India: 59% faced irregular device servicing and support in semi-urban regions.

Future Investment Priorities

Alignment

• 76% of global medtech firms plan to invest in drug-coated and AI-assisted catheter systems.

Divergence

• USA: 64% focused on integrating remote diagnostic and imaging platforms.
• Europe: 55% planned to invest in green-compliant stents and device packaging.
• India/China: 61% leaned toward local production facilities to cut cost and logistics dependency.

Regulatory Impact

• USA: 71% felt new CMS reimbursement criteria for outpatient PAD treatments positively influenced angioplasty demand.
• Western Europe: 79% rated EU MDR and environmental mandates as a dual-edged sword: quality driver and go-to-market barrier.
• India/China/Japan: Only 38% viewed regulation as a key industry driver-citing low enforcement and delayed tech approvals.

Conclusion: Variance vs. Consensus

High Consensus

• Stakeholders globally agree on the need for minimally invasive, high-efficiency, and cost-effective procedures, especially in aging populations.

Key Variances

• USA/Europe: Driving innovation with premium, AI-integrated solutions.
• India/China: Seeking access and scale via affordability and local production.
• Japan: Pushing compact and time-efficient systems to serve high-volume urban hospitals.

Strategic Insight

• A localized strategy will outperform standard global rollouts. High-tech innovation should pair with affordability models in APAC, while Western players must stay ahead in regulatory compliance and green technology.

Policy & Regulatory Impact by Country

Countries/Region	Policy & Regulatory Impact
United States	CMS expanded reimbursement for outpatient PAD treatments, boosting procedural volume in ambulatory surgical centers (ASCs). - FDA requires 510(k) clearance or PMA for devices; DCBs and bioresorbable scaffolds need clinical efficacy data. - HIPAA and interoperability policies apply to AI-integrated systems.
Western Europe (EU)	EU MDR (Medical Device Regulation) has increased documentation and clinical evidence requirements, delaying industry entry for new angioplasty tools. - CE Mark is mandatory for all devices. - Green compliance regulations encourage use of recyclable materials and low-impact packaging.
India	CDSCO oversees angioplasty device approvals under the Medical Devices Rules, 2017. - Importers must obtain registration certificates; local trials increasingly required. - No universal reimbursement framework yet, creating pricing pressure in public hospitals.
China	NMPA mandates localized clinical trials for high-risk Class III devices like angioplasty catheters and DCBs. - Government favors domestic manufacturers via procurement policies under the “Made in China 2025” strategy. - GHTF compliance gaining traction.
Japan	PMDA regulates angioplasty devices under the Pharmaceuticals and Medical Devices Act (PMD Act). - Shonin approval needed, with stringent safety and efficacy data. - Cost control policies affect high-end device adoption; reimbursement revisions occur every 2 years.

Market Share of Leading Companies

Boston Scientific CorporationEstimated Industry Share: ~20-25%

A global leader with a strong portfolio in drug-coated balloons (DCBs) and stents. Its Ranger™ DCB and Innova™ stent system dominate several international industries.

Medtronic plcEstimated Industry Share: ~18-22%

Offers an extensive range of peripheral vascular solutions including the IN.PACT™ Admiral DCB, widely used for PAD. Maintains high industry penetration in North America and Europe.

Abbott LaboratoriesEstimated Industry Share: ~15-18%

A major player with innovations like the Omnilink Elite™ Vascular Balloon-Expandable Stent. Strong growth in Asia-Pacific due to regulatory clearances and pricing flexibility.

BD (Becton, Dickinson and Company)Estimated Industry Share: ~10-12%

Focused on cost-effective PTA balloon catheters. Gains traction in emerging industries due to high-volume manufacturing and supply chain optimization.

Cook MedicalEstimated Industry Share: ~8-10%

Known for its niche portfolio of peripheral intervention devices. Focuses on physician training and direct hospital partnerships for industry expansion.

Cardinal Health (Cordis)Estimated Industry Share: ~5-7%

Gains industry share in Latin America and parts of Asia with accessible peripheral stent systems. Strong distribution networks drive reach.

BiotronikEstimated Industry Share: ~3-5%

European-based firm with a selective but innovative peripheral device lineup. Focuses on research-driven growth and regional partnerships.

Key Developments in 2024

• Medtronic made a significant move in January 2024 by initiating a large-scale clinical trial to evaluate long-term safety and patency of its IN. PACT™ 018 DCB platform across multiple geographies, including Asia-Pacific and Latin America. This global registry is intended to strengthen clinical backing amid competition.
• BD (Becton, Dickinson and Company) expanded its manufacturing facility in Suzhou, China, in July 2024 to cater to the Asia-Pacific region with faster turnaround and cost-efficient devices for public health procurement.
• In September 2024, Cook Medical partnered with India-based hospital chain Narayana Health to launch a PAD awareness and screening campaign tied to distribution of its peripheral balloon catheters. This initiative aligns with India’s National Program for Non-Communicable Diseases.
• Cordis, now independently managed under Cardinal Health, invested in strengthening its distribution logistics network in Brazil and Mexico in mid-2024 to better serve public-sector hospitals in rural zones.

Segment Wise Analysis

By Product

The balloon catheters are expected to dominate the peripheral angioplasty industry with a CAGR of 5.2% from 2025 to 2035. The balloon catheters are expected to remain a foundational component of peripheral angioplasty procedures due to their minimally invasive nature and effectiveness in treating stenotic lesions. Advancements in drug-coated balloon technologies are expected to enhance clinical outcomes, particularly in cases of recurrent peripheral arterial disease.

Stents, especially self-expanding and drug-eluting variants, will likely see sustained demand owing to their ability to reduce restenosis and provide long-term vessel patency. While innovation in stent design has plateaued in recent years, manufacturers are now focusing on bioresorbable stents and hybrid solutions that combine mechanical support with pharmacological benefits.

Guidewires will also maintain steady growth throughout the forecast period, as these devices are essential for navigating complex vascular anatomy during angioplasty. The rise in chronic lifestyle diseases, coupled with improved operator training and procedural volumes in emerging industries, will drive sustained adoption across all three product categories.

By End User

The hospitals segments are expected to dominate the peripheral angioplasty industry with a CAGR of 6.3% from 2025 to 2035. Hospitals will continue to dominate the end-user segment of the peripheral angioplasty industry between 2025 and 2035, largely due to their established infrastructure, multidisciplinary care offerings, and ability to manage complex vascular cases. Tertiary hospitals and government-run medical centers will also benefit from increased public sector investment in cardiovascular health infrastructure across both developed and developing regions.

Ambulatory surgical centers are poised for robust expansion during the same period, as payers and patients increasingly prioritize lower-cost, outpatient alternatives for routine endovascular procedures. These centers benefit from faster turnaround times and reduced overheads, making them attractive venues for elective angioplasties.

Cardiac catheterization centers will see growing utilization in urban healthcare ecosystems, particularly in North America and Europe, where cardiovascular screening programs are routinely integrated into preventive care. These centers offer high procedural efficiency, advanced imaging modalities, and shorter patient recovery times-factors that align well with the shift toward value-based vascular interventions.

Country Wise Analysis

United States

The United States peripheral angioplasty industry is anticipated to grow with a CAGR of 7.9% in the forecast period (2025 to 2035). This growth is attributed to a rise in incidents of peripheral artery disease (PAD), especially in the geriatric section and the use of diabetes and obesity.

Broad insurance coverage for angioplasty procedures by Medicare and commercial payers will remain supportive of procedural volumes. Plus, the move to outpatient is driving investments in ambulatory surgical centers and cardiac catheterization laboratories.

The USA also has a strong R&D ecosystem, with big players including Boston Scientific and Medtronic releasing next-generation drug-coated balloons and stents. The FDA’s 510(k) and PMA pathways, which provide regulatory stability while giving companies the opportunity to bring new ideas to industry without obtaining their approval too slowly, is also a large factor in the US’s growing position in this space.

United Kingdom

Demand for peripheral angioplasty in the United Kingdom is expected to rise at a CAGR of around 6.9% during 2025 to 2035. This is increasingly being recognized by the National Health Service (NHS) as a crucial area of focus in the Long-Term Plan for Cardiovascular Disease Management (CVD), which, in turn, is helping to raise awareness and improve the early diagnosis of PAD.

Despite a continued hospital-centric approach with procedural care in the UK, some incremental adoption has taken place with outpatient angioplasty services being established in a few urban based centers. However, some friction still exists for importing devices, albeit with benefits for key players from the ease of regulation alignment via the UKCA marking process post-Brexit.

Venture funding also has been complemented by government investments in the fields of digital health and tele-cardiology that have further enabled more personalized treatment pathways. With the presence of clinical registries and multi-center research programs, the UK has undoubtedly become a valuable refuge for the evaluation of new endovascular technologies and procedural best practices.

France

The French Peripheral Angioplasty Industry is expected to grow at a CAGR of around 6.8% during the forecast period. As the country has a highly centralized public health system with widespread access to PAD diagnosis and intervention services, the demand for peripheral vascular procedures is kept high. In France, where minimal invasive techniques are also much appreciated, drug-eluting stents and balloon catheters are extremely popular.

Via the French Social Security Financing Law, this plan classified angioplasty in chronic care plans simplifying the reimbursement mechanisms to local players and multinational corporations. French hospitals are also among both participants in European clinical trials, as well as the European device performance benchmarking, to provide strong data for product efficacy. Investments in hybrid operating rooms and vascular specialist training forge a powerful ecosystem in which procedural growth can continue to thrive.

Germany

Germany Peripheral Angioplasty Industry is anticipated to grow at a steady CAGR of 7.5% during the forecast period. Germany is at the forefront of Europe regarding procedural volume and technology because of its decentralized healthcare structure and many specialized vascular centers. Strong public-private partnerships help procure advanced medical devices, and patients enjoy relatively short wait times for PAD diagnosis and treatment.

Drug-coated balloon angioplasty has been embraced by German hospitals, where many of the clinical trials used to set wider EU device guidelines originate. The country’s health insurers are very much on board with minimally invasive interventions, especially in older populations. Local manufacturers and regional distributors have strong relationships with university hospitals, accelerating early technology rollouts and product feedback cycles.

Italy

The peripheral angioplasty industry in Italy is anticipated to be growing at a compound annual growth rate (CAGR) of 6.6% during the forecast period. Italy has also improved its vascular infrastructure in recent years, particularly in Northern Italy, even though the country’s healthcare system is publicly funded and regionally governed. More investments in vascular diagnostic tools as well as intervention capabilities are being observed due to growing prevalence of diabetes, smoking and hypertension leading to increased PAD bioburden.

Training programs supported by European vascular societies and integration of hybrid catheterization labs in tertiary centers across Italy. New peripheral angioplasty devices are more slowly adopted than in Germany and France, but also more and more local physicians join multicenter studies exploring long-term results. Although reimbursement remains a struggle, device companies are targeting metropolitan areas for higher-margin procedures.

New Zealand

The peripheral angioplasty industry in New Zealand is likely to grow at a CAGR of 6.1% between 2025 and 2035. New Zealand faces increasing cases of PAD, especially among its Māori and Pasifika populations, who show higher incidences of diabetes and lifestyle-related risk factors. However, procedural access remains uneven between urban and rural populations due to centralized vascular facilities.

The public health system covers most angioplasty procedures but long wait times can delay timely intervention. The government is gradually expanding investments in cardiovascular infrastructure through regional health boards.

Private hospital networks and telehealth collaborations are beginning to facilitate faster diagnostics. Device penetration remains low compared to Australia, but New Zealand’s close regulatory alignment with Australian standards helps streamline device approval and procurement.

South Korea

The peripheral angioplasty industry in South Korea is forecast to expand at a CAGR of 7.6% through 2035. South Korea’s rapid technological adoption, combined with a strong national health insurance system, has led to increased demand for vascular interventions. Urban hospitals, especially in Seoul and Busan, offer advanced catheterization labs with imaging integration and robotic assistance.

Local manufacturers are also entering the angioplasty device space, supported by government funding through the Ministry of Health and Welfare’s innovation programs. PAD screening initiatives have expanded under the national preventive health plan, encouraging earlier-stage intervention.

Additionally, collaborations with global medical device firms are fueling faster access to high-end drug-eluting balloons and next-gen guidewires, supporting South Korea’s emergence as a regional hub for peripheral vascular care.

Japan

The peripheral angioplasty industry in Japan is projected to grow at a CAGR of 6.4% over the 2025 to 2035 period. Despite its aging population and advanced medical infrastructure, Japan exhibits a conservative approach to adopting new angioplasty devices due to high regulatory scrutiny under the PMDA. However, once approved, technologies see high uptake in academic medical centers.

The government continues to invest in preventive cardiovascular health, and angioplasty procedures for PAD are fully reimbursed under national insurance, creating favorable economics for high-volume hospitals.

Japan is also leading in hybrid operating room installations and robotic-assisted vascular procedures. While drug-coated balloons are gradually gaining traction, Japanese clinicians still favor long-term efficacy data before widespread adoption. Local manufacturers are developing cost-effective stent systems that meet both quality and price expectations.

China

China's peripheral angioplasty industry is expected to grow at a CAGR of 8.2% from 2025 to 2035, the highest among major economies. This surge is driven by rising lifestyle diseases and government focus on expanding access to vascular procedures under its “Healthy China 2030” initiative. Tier 1 and Tier 2 cities are witnessing the establishment of advanced vascular intervention centers, while rural penetration remains limited but is improving.

Domestic manufacturers benefit from government procurement incentives and are rapidly closing the quality gap with foreign brands. The National Medical Products Administration (NMPA) has streamlined clinical trial approvals, accelerating the introduction of drug-eluting and bioresorbable devices.

International companies are partnering with local firms to navigate the regulatory environment and capture volume-driven growth. China’s growing healthcare infrastructure and middle-class expansion support long-term angioplasty demand.

Australia

The peripheral angioplasty industry in Australia is forecast to grow at a CAGR of 6.7% from 2025 to 2035. Australia maintains a dual public-private healthcare structure that allows both Medicare-covered and out-of-pocket angioplasty procedures.

The country has seen steady growth in PAD awareness, thanks to national health campaigns and targeted cardiovascular screening programs. Most angioplasty procedures are concentrated in metropolitan regions such as Sydney and Melbourne, although telehealth expansion is improving rural access.

Australian hospitals are among the earliest adopters of global innovations, often piloting next-gen balloon catheters and stents under post-industry surveillance agreements. Regulatory efficiency under the Therapeutic Goods Administration (TGA) encourages quick but safe device adoption. Continued investment in cardiovascular research and skilled labor training will support the industry's upward trajectory through 2035.

Key Players

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Cordis (a Cardinal Health company)
• Terumo Corporation
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Cook Medical
• Becton, Dickinson and Company (BD)
• Koninklijke Philips N.V.
• Teleflex Incorporated
• Endocor GmbH
• iVascular S.L.U.
• Lepu Medical Technology Co., Ltd.
• MicroPort Scientific Corporation

Peripheral Angioplasty Market Segmentation by Key Investment Segments

By Product:

The industry is segmented into balloon catheters, stents, and guidewires.

By End User:

The industry is segmented into hospitals, ambulatory surgical centers, and cardiac catheterization centers.

By Region:

The industry is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa.